CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND^® (Mitapivat) to Treat Children with Rare Blood Disease

Centogene N.V. announced that it has expanded its long-standing PYRUKYND® partnership with Agios Pharmaceuticals, Inc. Agios’ PYRUKYND® is a first-in-class, selective, small molecule activator of the pyruvate kinase enzyme.